Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK 1,251.50
-33.50 (-2.61%)
Apr 4, 2025, 4:59 PM CET
Genmab Revenue
In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.
Revenue
21.53B
Revenue Growth
+30.67%
P/S Ratio
3.83
Revenue / Employee
8.03M
Employees
2,682
Market Cap
81.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 290.40B |
| Coloplast | 27.45B |
| Demant | 22.42B |
| Zealand Pharma | 62.69M |
| ALK-Abelló | 5.54B |
| H. Lundbeck | 22.00B |
| Ambu A/S | 5.65B |
| GN Store Nord | 17.99B |
Genmab News
- 3 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
- 3 days ago - Genmab drops as Bernstein cuts on Darzalex patent cliff - Seeking Alpha
- 4 days ago - TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - Business Wire
- 4 days ago - TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - GlobeNewsWire
- 4 days ago - Transactions in connection with share buy-back program - GlobeNewsWire
- 8 days ago - Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer - Benzinga
- 8 days ago - Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer - Benzinga
- 8 days ago - Genmab and BridgeBio Pharma announce Japan approval for their treatments - Seeking Alpha